Russell Investments Group Ltd. Boosts Holdings in Harrow, Inc. (NASDAQ:HROW)

Russell Investments Group Ltd. increased its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 138.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,712 shares of the company's stock after acquiring an additional 21,894 shares during the period. Russell Investments Group Ltd. owned about 0.11% of Harrow worth $1,265,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in HROW. AlphaQuest LLC raised its holdings in Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after acquiring an additional 2,889 shares during the last quarter. Maridea Wealth Management LLC bought a new stake in Harrow during the 4th quarter worth approximately $222,000. KLP Kapitalforvaltning AS bought a new position in shares of Harrow in the fourth quarter worth about $235,000. China Universal Asset Management Co. Ltd. grew its stake in Harrow by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock valued at $253,000 after acquiring an additional 727 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Harrow in the 3rd quarter worth approximately $271,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $57.00 target price on shares of Harrow in a report on Monday, March 31st. B. Riley dropped their target price on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st.

Harrow Trading Down 1.1 %

NASDAQ:HROW traded down $0.27 on Friday, reaching $24.80. The company's stock had a trading volume of 64,837 shares, compared to its average volume of 502,207. Harrow, Inc. has a 12-month low of $9.86 and a 12-month high of $59.23. The stock has a 50 day moving average price of $25.57 and a 200 day moving average price of $35.00. The firm has a market cap of $884.22 million, a price-to-earnings ratio of -26.29 and a beta of 0.46. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. The company had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. On average, equities analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.